Argentina Clinical Evidence Requirements: When ANMAT Demands Clinical Studies

1. Key takeaways

Argentina assesses clinical evidence through a 3-tier evidence package, and the trigger is a judgment of evidentiary sufficiency rather than a fixed class threshold: Class III/IV usually require clinical evaluation documentation; if the technical report cannot sufficiently demonstrate the safety and effectiveness of the product, ANMAT will require clinical studies on that product.

This wording supports 2 inferences: a product supported by adequate clinical literature or foreign clinical data may pass with a clinical evaluation report; and a wholly new design, without predicate products or adequate literature support, will almost certainly be required to conduct clinical studies. Planning the evidence strategy around this sufficiency judgment, instead of assuming that a class label alone settles the question, is the core discipline of the Argentine clinical pathway.

The sufficiency judgment also has a practical asymmetry worth internalizing: the burden sits with the applicant to demonstrate sufficiency, not with ANMAT to prove insufficiency. A sparse clinical evaluation invites the clinical-study requirement by default, while a thorough one shifts the discussion toward whether the assembled evidence is adequate. Since clinical studies are the most expensive outcome available in this framework, every hour spent strengthening tiers one and two is an investment against the third tier being activated.

2. Legal basis

The instruments span the full evidence lifecycle: GMC/RES 25/21 and Disposición ANMAT 64/2025 define when clinical documentation is demanded in the registration review, Disposición ANMAT 7516/2025 sets the quality baseline for any clinical study actually conducted, and Disposición ANMAT 8194/2023 carries the evidence obligation into the post-market phase through continuous safety and performance data collection.

Read as a whole, the framework rewards applicants who treat clinical evidence as a continuum rather than a gate. The same literature searches, predicate comparisons and data collections that answer the registration question continue to answer the post-market and renewal questions afterward, and organizing the evidence once, in a structure that can be extended, avoids rebuilding it at each phase of the product lifecycle.

3. Expert insights

Insight 1: whether the technical report sufficiently demonstrates safety and effectiveness is a judgment with room to be won. Companies can lower the probability of being required to conduct clinical studies by raising the quality of the technical report and the clinical evaluation report. Three actions matter most: transferring foreign clinical data completely, performing a systematic comparison with predicate products, and carrying out a thorough literature search and analysis. Each of the three directly strengthens the sufficiency case that the reviewer must accept or refute.

Insight 2: Disposición 7516/2025 adopting ICH E6 (R3) raises the execution baseline for clinical studies. If a clinical study in Argentina is genuinely required, the protocol design, conduct and records must comply with ICH E6 (R3). Although this standard primarily targets clinical pharmacology studies, it represents ANMAT’s uniform expectation of clinical study quality, and device studies will be measured against the same expectations of documented, controlled conduct.

Insight 3: clinical evidence does not end once it has been submitted. The vigilance obligations of Disposición 8194/2023 require continuous collection of safety and performance data for the product. Post-market clinical follow-up (PMCF) data obtained after the certificate is granted serve both as a compliance obligation and as favorable evidence at renewal, which makes a disciplined PMCF program one of the few investments that pays off twice.

4. Practical recommendations

1. Prepare the three-tier evidence package. Tier one: the technical report (Annex V); tier two: the clinical evaluation report, including predicate comparison and a systematic literature search and analysis; tier three: a clinical study protocol held in reserve, ready to activate when ANMAT requires it, so that a demand for studies does not restart the project from zero.
2. Attach an applicability justification to foreign clinical data. Explain differences in population, use environment and operators, and argue the extrapolation of the data to the Argentine population rather than assuming the transfer is self-evident.
3. Make the predicate comparison parameter-specific. The comparison of biological equivalence and physicochemical performance must be listed item by item; conclusory statements without a parameter table will not survive review.
4. Bank PMCF data for renewal. Continue collecting Argentine local use data after the certificate is granted, building the evidence update for the 5-year renewal well before the renewal file is opened.

5. Verification checklist

• □ Product classification confirmed, including whether the class usually requires clinical evaluation documentation
• □ Technical report (Annex V) completed and sufficient to support a preliminary conclusion
• □ Clinical evaluation report completed, including predicate comparison and a systematic literature search
• □ Applicability justification attached to foreign clinical data
• □ Clinical study protocol prepared as the reserve tier
• □ If a clinical study in Argentina is required, preparation made in accordance with ICH E6 (R3)
• □ Post-market clinical follow-up data collection planned for after the certificate is granted

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.